Want to see AU:AYA full AI Analyst Report?
AYA Stock Chart & Stats
AU$4.99
-AU$0.02(-0.35%)
At close: 4:00 PM EDT
AU$4.99
-AU$0.02(-0.35%)
Day’s Range― - ―
52-Week RangeAU$2.12 - AU$6.49
Previous CloseN/A
Volume465.77K
Average Volume (3M)895.09K
Market Cap
AU$536.06M
Enterprise ValueAU$920.15
Total Cash (Recent Filing)AU$74.17M
Total Debt (Recent Filing)AU$247.00K
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Mar 02, 2027EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding163,433,620
10 Day Avg. Volume1,331,175
30 Day Avg. Volume895,085
Financial Highlights & Ratios
PEG Ratio6.46
Price to Book (P/B)11.56
Price to Sales (P/S)32321.70
P/FCF Ratio-56.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.00Price Target Upside20.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.12
Revenue Forecast (FY)AU$6.88M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces near-term solvency and refinancing pressure, preserving financial flexibility while Artrya develops its products. This gives the company more capacity to direct available resources toward commercialization and operations without a substantial interest burden weighing on cash flow.
Specialized Clinical AIA focused clinical application in cardiovascular disease detection gives Artrya a clearly defined healthcare technology niche. Decision-support software that helps clinicians interpret diagnostic data can support institutional adoption if it becomes embedded in hospital, imaging, and cardiology workflows.
Recurring Revenue Model PotentialLicensing, subscription, and usage-based structures could create recurring or repeat revenue as healthcare providers process more studies through the platform. This model can improve revenue visibility and scalability over time, although the pack does not provide commercial pricing or contract detail.
Bears Say
Minimal Revenue BaseThe extremely small revenue base shows that commercialization has not yet translated into meaningful financial scale. Even with a promising software model, the company must achieve substantial customer adoption and usage before revenue can support its operating structure or reduce dependence on funding.
Widening LossesWidening losses indicate that operating expenses substantially exceed the revenue currently generated by the business. Persistent deterioration increases the amount of capital required to reach sustainability and suggests that operating leverage has not yet emerged from the company’s commercialization efforts.
Persistent Cash BurnContinued negative operating and free cash flow means Artrya is not funding its activities internally. Worsening cash consumption can require further external financing, potentially constraining strategic flexibility and weakening the balance sheet if losses continue without a meaningful improvement in commercial receipts.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$2.12 and its highest was AU$6.49 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$536.06M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Mar 02, 2027 which is in 165 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Aug 19, 2026. The company reported -AU$0.089 earnings per share for the quarter, missing the consensus estimate of -AU$0.055 by -AU$0.034.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate is -0.08.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 163,433,620 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.089 in its last earnings report, missing expectations of -AU$0.055. Following the earnings report the stock price went down -1.274%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.00 (20.24% Upside)
AU$6.00 (20.24% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
58.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
260.49%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Artrya Limited
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.00
▲(20.24% Upside)
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
Singular Health Group Ltd
―
Alcidion Group Limited
―









